NASDAQ: CMPS - COMPASS Pathways plc

Yield per half year: -50.9%
Dividend yield: 0.00%
Sector: Healthcare

Share chart COMPASS Pathways plc

Extended chart Simple chart
Financial Markets by TradingView

About COMPASS Pathways plc

COMPASS Pathways plc работает как компания по охране психического здоровья в Соединенном Королевстве и Соединенных Штатах. Он разрабатывает COMP360, препарат псилоцибина, который находится в стадии клинических испытаний IIb для лечения пациентов с устойчивой к лечению депрессией. Компания ранее была известна как COMPASS Rx Limited и сменила свое название на COMPASS Pathways plc в августе 2020 года. COMPASS Pathways plc была зарегистрирована в 2020 году и базируется в Чешире, Великобритания.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-09-18
ISIN US20451W1018
Industry Health Care Providers & Services
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт https://www.compasspathways.com
Цена ао 3.56
Change price per day: -4.56% (3.73)
Change price per week: -11.44% (4.02)
Change price per month: -13.38% (4.11)
Change price per 3 month: -19.27% (4.41)
Change price per half year: -50.9% (7.25)
Change price per year: -63.65% (9.795)
Change price per 3 year: -74.84% (14.15)
Change price per 5 year: 0% (3.56)
Change price per 10 year: 0% (3.56)
Change price per year to date: -5.82% (3.78)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2 7
P/E 0 0
EV/EBITDA -1.92 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -43.09 0
ROE, % -52.68 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2272 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 486.29 10
Yield EPS, % 157.95 10
Total: 8
More

Transaction date Date of disclosure Insider Type Price Volume Quantity Share before, % Share after, % Document
26.09.2024 27.09.2024 ATAI Life Sciences N.V.
10% Owner		 Sale 6.05 16 093 000 2660000 0 -6.37 link
17.04.2024 18.04.2024 Malievskaia Ekaterina
10% Owner		 Sale 8.78 95 263 10850 0 -0.03 link
17.04.2024 18.04.2024 Goldsmith George Jay
10% Owner		 Sale 8.78 95 263 10850 0 -0.03 link
16.04.2024 18.04.2024 Malievskaia Ekaterina
10% Owner		 Sale 8.53 203 705 23881 0 -0.06 link
16.04.2024 18.04.2024 Malievskaia Ekaterina
10% Owner		 Sale 8.53 203 696 23880 0 -0.06 link
16.04.2024 18.04.2024 Goldsmith George Jay
10% Owner		 Sale 8.53 203 696 23880 0 -0.06 link
16.04.2024 18.04.2024 Goldsmith George Jay
10% Owner		 Sale 8.53 203 705 23881 0 -0.06 link
13.03.2024 14.03.2024 Malievskaia Ekaterina
Director		 Sale 10.8 185 792 17203 0 -0.04 link
13.03.2024 14.03.2024 Goldsmith George Jay
Director		 Sale 10.8 185 792 17203 0 -0.04 link
12.03.2024 14.03.2024 Malievskaia Ekaterina
Director		 Sale 10.58 166 529 15740 0 -0.04 link
12.03.2024 14.03.2024 Goldsmith George Jay
Director		 Sale 10.58 166 529 15740 0 -0.04 link
14.12.2023 15.12.2023 Goldsmith George Jay
Director		 Sale 7.81 10 754 1377 0 0 link
14.12.2023 15.12.2023 Malievskaia Ekaterina
Director		 Sale 7.81 10 754 1377 0 0 link
13.12.2023 15.12.2023 Goldsmith George Jay
Director		 Sale 7.82 22 326 2855 0 -0.01 link
13.12.2023 15.12.2023 Malievskaia Ekaterina
Director		 Sale 7.82 22 326 2855 0 -0.01 link

Institutions Volume Share, %
Tcg Crossover Management, Llc 3858000 6.23
ARK Investment Management, LLC 2618871 4.23
Paradigm Biocapital Advisors LP 2265988 3.66
Vivo Capital, LLC 1608000 2.6
Citadel Advisors Llc 1565000 2.53
RA Capital Management, L.P. 1286000 2.08
Soleus Capital Management, L.P. 964550 1.56
Aisling Capital Management LP 964500 1.56
Rosalind Advisors, Inc. 798500 1.29
Affinity Asset Advisors, LLC 550000 0.89

ETF Share, % Profitability for 1 year, % Dividends, %
AdvisorShares Psychedelics ETF 6.71965 845.99 0.20
PSYK ETF 5.26 0
ARK Genomic Revolution ETF 1.06932 -8.08 0.05494
Virtus LifeSci Biotech Clinical Trials ETF 0.82737 63.04 0.33
Putnam Sustainable Future ETF 0.29668 32.87 0.70689
SPDR S&P International Small Cap ETF 0.02797 8.94 3.10348



Head Job title Payment Year of birth
Mr. Stephen D. Schultz Senior Vice President of Investor Relations N/A
Dr. Greg Ryslik Ph.D. Chief Technology Officer N/A
Ms. Anne Benedict Chief People Officer N/A
Mr. Christopher Williams Chief Communications Officer N/A
Mr. Lars Christian Wilde Senior Advisor N/A 1986 (39 years)
Mr. Matthew Allen Owens General Counsel & Chief Legal Officer 659.53k 1977 (48 years)
Ms. Teri Loxam M.B.A. CFO, Principal Financial Officer & Principal Accounting Officer N/A 1973 (52 years)
Mr. Kabir Kumar Nath M.A., M.B.A. CEO & Director 1964 (61 year)
Dr. Guy Goodwin Chief Medical Officer 1948 (77 years)
Dr. Susan C. Stansfield Ph.D. Advisor

Address: United Kingdom, Altrincham WA DT, 1 Ashley Road - open in Google maps, open in Yandex maps
Website: https://www.compasspathways.com